Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

ClinicalTrials.gov ID: NCT02066532

Public ClinicalTrials.gov record NCT02066532. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 4, 2026, 3:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to examine the safety and efficacy of Ruxolitinib in combination with Trastuzumab in treatment of HER2 positive metastatic breast cancer. Ruxolitinib (Jakafi) is an Food and Drug Administration (FDA) approved treatment for myelofibrosis (a disease of the bone marrow), but its safety and efficacy in breast cancer patients is not known. Trastuzumab (Herceptin) is an FDA-approved treatment for HER2 positive breast cancer. The safety and efficacy of both treatments given in combination is not known. It is hypothesized that Ruxolitinib in combination with Trastuzumab will demonstrate efficacy in treating Metastatic HER2 Positive Breast Cancer subjects, and will have a tolerable safety profile in this patient population.

Study identification

NCT ID: NCT02066532
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Dawn L. Hershman; Other
Enrollment: 32 participants

Conditions and interventions

Conditions

Interventions

Ruxolitinib Drug
Trastuzumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2014 (Actual)
Primary completion: Oct 14, 2020 (Actual)
Completion: Oct 14, 2020 (Actual)
Last update posted: Aug 24, 2023

2014 – 2020

United States locations

U.S. sites: 4
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Mount Sinai Medical Center	New York	New York	10029	—
Columbia University Medical Center	New York	New York	10032	—
New York Hospital-Weill Cornell Medical Center	New York	New York	10065	—
Montefiore Medical Center	New York	New York	10461	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02066532, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 24, 2023 · Synced Oct 4, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02066532 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →